Key points from article :
Four peer-reviewed papers cover LyGenesis’ work on liver and kidney regeneration.
Success of their preclinical studies firms-up the foundation for their first human clinical trial to regenerate organs.
Liver paper 1 demonstrated that mini-livers could be grown using the lymph node as a bioreactor.
Liver paper 2 showed that these regenerated livers could cure tyrosinemia Type I(human liver disease) in pigs.
Kidney paper 1 showed that human ectopic kidney tissues could also be grown using the lymph node as a bioreactor.
Kidney paper 2 looked at molecular signalling crucial for engrafted kidney tissue to grow and function properly.
"We are focused on keeping our momentum, closing a $25M B-round of financing, launching our first clinical trial, and developing our pipeline of organs for regeneration, including the thymus, kidney, and pancreas" - Michael Hufford, CEO
Latest research by LyGenesis published in Science Direct.
